Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of crizotinib in ALK mutant non-small cell lung cancers that are positive by IHC but negative by FISH compared to FISH positive cases.

Indian journal of cancer - 1 Jan 2000

Zanwar Saurabh, Noronha Vanita, Joshi Amit, Patil Vijay M, Kaushal Rajiv, Chougule Anuradha, Janu Amit, Mahajan Abhishek, Kapoor Akhil, Prabhash Kumar

Abstract excerpt

BACKGROUND: A small proportion of Non-Small Cell Lung Cancers (NSCLC) are detected with Anaplastic Lymphoma Kinase (ALK) mutation by immunohistochemistry (IHC) but are negative by Fluorescence in situ Hybridization (FISH). Data on responses and outcome of this subset of patients when treated with crizotinib is limited. We analyzed the outcomes of such patients who received crizotinib. PATIENTS AND METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Crizotinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Gene Rearrangement

Share to In Situ Hybridization, Fluorescence

Share to Pyrazoles

Share to Pyridines

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 30082557
DOI: 10.4103/ijc.IJC_532_16

Genes

ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of crizotinib in ALK mutant non-small cell lung cancers that are positive by IHC but negative by FISH compared to FISH positive cases.PMID 30082557Read ↗

The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy.Semantic proximity Read ↗

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisSemantic proximity Read ↗

TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinibSemantic proximity Read ↗

Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.Semantic proximity Read ↗

Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies.Semantic proximity Read ↗

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.Semantic proximity Read ↗

Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.Semantic proximity Read ↗

A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.Semantic proximity Read ↗

Management of NSCLC: focus on crizotinib.Semantic proximity Read ↗

Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitorsSemantic proximity Read ↗

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung CancersSemantic proximity Read ↗

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK -Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ HybridizationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.